文献速递肝病消化道出血

血小板活化降低可预测肝硬化患者肝功能失代偿与死亡

Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
PubMed 文献 · Hepatology · 2023-12-27

该前瞻性研究纳入107例肝硬化患者,同日行肝静脉压力梯度(HVPG)与血小板活化检测,随访25.3个月(IQR:15.7-31.2),29例发生首次/再次失代偿、17例死亡。PAR-4诱导的血小板活化较高与失代偿风险较低独立相关,PAR-1诱导的血小板活化较高与生存期较长独立相关;肾上腺素诱导的血小板活化较高与血栓栓塞及门静脉血栓风险增加相关。

要点

  • PAR-4诱导血小板活化每升高100 MFI,失代偿风险校正HR为0.95(95%CI:0.90-0.99;p=0.036)。
  • PAR-1诱导血小板活化每升高100 MFI,生存期较长校正HR为0.93(95%CI:0.87-0.99;p=0.040)。
  • 肾上腺素诱导血小板活化每升高10 MFI,血栓栓塞风险HR为1.07(95%CI:1.02-1.12;p=0.007)。

核心结论

  • 保留的PAR-1和PAR-4诱导血小板活化与较低的失代偿和死亡风险相关。
  • 相反,较高的肾上腺素诱导血小板活化是血栓栓塞和门静脉血栓(PVT)的危险因素。

研究设计与样本

  • 前瞻性纳入107例肝硬化患者,同日行肝静脉压力梯度(HVPG)和血小板活化检测。
  • 血小板活化采用流式细胞术评估PAR-1、PAR-4或肾上腺素刺激后的活化。
  • 随访25.3个月(IQR:15.7-31.2),观察首次/再次失代偿、死亡、出血和血栓栓塞事件。

主要发现

  • 随访期间29例发生首次/再次失代偿,17例死亡。
  • 较高的PAR-4诱导血小板活化与较低的失代偿风险独立相关(每100 MFI校正HR:0.95,95%CI:0.90-0.99;p=0.036)。
  • 较高的PAR-1诱导血小板活化与较长的生存期独立相关(每100 MFI校正HR:0.93,95%CI:0.87-0.99;p=0.040)。
  • 血栓栓塞事件发生于8例患者,其中75%为非肿瘤性门静脉血栓(PVT)。
  • 较高的肾上腺素诱导血小板活化与血栓栓塞风险增加相关(每10 MFI HR:1.07,95%CI:1.02-1.12;p=0.007),与PVT风险增加相关(每10 MFI HR:1.08,95%CI:1.02-1.14;p=0.004)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with cirrhosis show alterations in primary hemostasis, yet prognostic implications of changes in platelet activation remain controversial, and assay validity is often limited by thrombocytopenia. We aimed to study the prognostic role of platelet activation in cirrhosis, focusing on bleeding/thromboembolic events, decompensation, and mortality. APPROACH AND RESULTS: We prospectively included 107 patients with cirrhosis undergoing a same-day hepatic venous pressure gradient (HVPG) and platelet activation measurement. Platelet activation was assessed using flow cytometry after protease-activated receptor (PAR)-1, PAR-4, or epinephrine stimulation. Over a follow-up of 25.3 (IQR: 15.7-31.2) months, first/further decompensation occurred in 29 patients and 17 died. More pronounced platelet activation was associated with an improved prognosis, even after adjusting for systemic inflammation, HVPG, and disease severity. Specifically, higher PAR-4-inducible platelet activation was independently linked to a lower decompensation risk [adjusted HR per 100 MFI (median fluorescence intensity): 0.95 (95% CI: 0.90-0.99); p =0.036] and higher PAR-1-inducible platelet activation was independently linked to longer survival [adjusted HR per 100 MFI: 0.93 (95% CI: 0.87-0.99); p =0.040]. Thromboembolic events occurred in eight patients (75% nontumoral portal vein thrombosis [PVT]). Higher epinephrine-inducible platelet activation was associated with an increased risk of thrombosis [HR per 10 MFI: 1.07 (95% CI: 1.02-1.12); p =0.007] and PVT [HR per 10 MFI: 1.08 (95% CI: 1.02-1.14); p =0.004]. In contrast, of the 11 major bleedings that occurred, 9 were portal hypertension related, and HVPG thus emerged as the primary risk factor. CONCLUSIONS: Preserved PAR-1- and PAR-4-inducible platelet activation was linked to a lower risk of decompensation and death. In contrast, higher epinephrine-inducible platelet activation was a risk factor for thromboembolism and PVT.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hofer BS, Brusilovskaya K, Simbrunner B, et al. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis. Hepatology. 2023. PMID: 38150294. doi:10.1097/HEP.0000000000000740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。